In this study, we present an 18-month serological follow-up of 294 patients with COVID-19 pneumonia. The aim was to assess the dynamics of serological response and its correlation with clinical worsening, as well as to describe clinical worsening determinants. Results of the study showed an early immunoglobulin M response, which clearly diminished starting at 4 months, but nonetheless, a small group of patients remained positive. As for immunoglobulin G, levels were higher up to 6 months in patients who presented clinical worsening during hospitalization. High titers of the immunoglobulin were maintained in all patients during follow-up, which would indicate that humoral immunity due to infection is long-lasting. Male sex, presence of myalgias and extensive radiological affectation were significantly correlated with clinical worsening.
In this 13-month follow-up study, we examined a cohort of vaccinated healthcare workers without prior SARS-CoV-2 infection to assess the humoral and cellular response to the BNT162b2 mRNA COVID-19 vaccine over time. We measured median immunoglobulin G and lymphocyte subpopulation levels after the first and second doses, at five months post-second dose, and before and after the third dose. Our findings evinced a remarkable initial cellular and humoral response to each vaccine dose, although a progressive decline suggests the potential need for long-term booster doses. Age analysis showed significantly higher immunoglobulin G levels in the younger group after the first dose administration, although these differences were not maintained in the following doses. Preserving cellular immunity could assure long-lasting protection against SARS-CoV-2 infection.